CERo Therapeutics Holdings (CERo Therapeutics Holdings) Long-Term Capital Lease Obligation : $2.35 Mil (As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Long-Term Capital Lease Obligation?

CERo Therapeutics Holdings's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2022 was $2.35 Mil.

CERo Therapeutics Holdings's quarterly Long-Term Capital Lease Obligation increased from . 20 ($0.00 Mil) to Dec. 2021 ($3.02 Mil) but then declined from Dec. 2021 ($3.02 Mil) to Dec. 2022 ($2.35 Mil).

CERo Therapeutics Holdings's annual Long-Term Capital Lease Obligation increased from . 20 ($0.00 Mil) to Dec. 2021 ($3.02 Mil) but then declined from Dec. 2021 ($3.02 Mil) to Dec. 2022 ($2.35 Mil).

CERo Therapeutics Holdings Long-Term Capital Lease Obligation Historical Data

The historical data trend for CERo Therapeutics Holdings's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Long-Term Capital Lease Obligation Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Long-Term Capital Lease Obligation

3.02

2.35

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Long-Term Capital Lease Obligation	3.02	2.35

CERo Therapeutics Holdings (NAS:CERO) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

CERo Therapeutics Holdings Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024